Understanding the Biology of Melanoma and Therapeutic Implications

Hematology/Oncology Clinics of North America

Volumn 28, Issue 3, 2014, Pages 437-453

  Sullivan, Ryan J ^a   Fisher, David E ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

BRAF; Immunotherapy; MITF; NRAS; Targeted therapy

Indexed keywords

CHIR 265; DABRAFENIB; IPILIMUMAB; LGX 818; MPDL 3280A; NIVOLUMAB; PEMBROLIZUMAB; SORAFENIB; UNCLASSIFIED DRUG; VEMURAFENIB; ONCOPROTEIN;

CANCER IMMUNOTHERAPY; DRUG TARGETING; GENE MUTATION; HUMAN; MELANOCYTE; MELANOMA; METASTATIC MELANOMA; MOLECULAR BIOLOGY; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; TRANSLATIONAL RESEARCH; ULTRAVIOLET RADIATION; BIOLOGICAL MODEL; DRUG EFFECTS; GENETIC PREDISPOSITION; GENETICS; MOLECULARLY TARGETED THERAPY; MUTATION; PROCEDURES; SKIN NEOPLASMS; TRENDS;

GENETIC PREDISPOSITION TO DISEASE; HUMANS; MELANOMA; MODELS, GENETIC; MOLECULAR TARGETED THERAPY; MUTATION; PROTO-ONCOGENE PROTEINS; SIGNAL TRANSDUCTION; SKIN NEOPLASMS;

EID: 84901437839     PISSN: 08898588     EISSN: 15581977     Source Type: Journal    
DOI: 10.1016/j.hoc.2014.02.007     Document Type: Review

References (121)

1. Chapman P.B., Hauschild A., Robert C., et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. NEngl J Med 2011, 364(26):2507-2516.
2. Flaherty K.T., Robert C., Hersey P., et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. NEngl J Med 2012, 367(2):107-114.
3. Hauschild A., Grob J.J., Demidov L.V., et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 2012, 380(9839):358-365.
4. Hodi F.S., O'Day S.J., McDermott D.F., et al. Improved survival with ipilimumab in patients with metastatic melanoma. NEngl J Med 2010, 363(8):711-723.
5. Robert C., Thomas L., Bondarenko I., et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. NEngl J Med 2011, 364(26):2517-2526.
6. Balch C.M., Gershenwald J.E., Soong S.J., et al. Final version of 2009 AJCC melanoma staging and classification. JClin Oncol 2009, 27(36):6199-6206.
7. Siegel R., Naishadham D., Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013, 63(1):11-30.
8. Mitra D., Luo X., Morgan A., et al. An ultraviolet-radiation-independent pathway to melanoma carcinogenesis in the red hair/fair skin background. Nature 2012, 491(7424):449-453.
9. D'Orazio J.A., Nobuhisa T., Cui R., et al. Topical drug rescue strategy and skin protection based on the role of Mc1r in UV-induced tanning. Nature 2006, 443(7109):340-344.
10. Cui R., Widlund H.R., Feige E., et al. Central role of p53 in the suntan response and pathologic hyperpigmentation. Cell 2007, 128(5):853-864.
11. Hodis E., Watson I.R., Kryukov G.V., et al. Alandscape of driver mutations in melanoma. Cell 2012, 150(2):251-263.
12. Price E.R., Fisher D.E. Sensorineural deafness and pigmentation genes: melanocytes and the Mitf transcriptional network. Neuron 2001, 30(1):15-18.
13. Garraway L.A., Widlund H.R., Rubin M.A., et al. Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature 2005, 436(7047):117-122.
14. Yokoyama S., Woods S.L., Boyle G.M., et al. Anovel recurrent mutation in MITF predisposes to familial and sporadic melanoma. Nature 2011, 480(7375):99-103.
15. Haq R., Shoag J., Andreu-Perez P., et al. Oncogenic BRAF regulates oxidative metabolism via PGC1alpha and MITF. Cancer Cell 2013, 23(3):302-315.
16. Haq R., Yokoyama S., Hawryluk E.B., et al. BCL2A1 is a lineage-specific antiapoptotic melanoma oncogene that confers resistance to BRAF inhibition. Proc Natl Acad Sci USA 2013, 110(11):4321-4326.
17. McGill G.G., Horstmann M., Widlund H.R., et al. Bcl2 regulation by the melanocyte master regulator MITF modulates lineage survival and melanoma cell viability. Cell 2002, 109(6):707-718.
18. Hemesath T.J., Price E.R., Takemoto C., et al. MAP kinase links the transcription factor Microphthalmia to c-Kit signalling in melanocytes. Nature 1998, 391(6664):298-301.
19. Wu M., Hemesath T.J., Takemoto C.M., et al. c-Kit triggers dual phosphorylations, which couple activation and degradation of the essential melanocyte factor Mi. Genes Dev 2000, 14(3):301-312.
20. Omholt K., Platz A., Kanter L., et al. NRAS and BRAF mutations arise early during melanoma pathogenesis and are preserved throughout tumor progression. Clin Cancer Res 2003, 9(17):6483-6488.
21. Sullivan R.J., Flaherty K. MAP kinase signaling and inhibition in melanoma. Oncogene 2012, 32(19):2373-2379.
22. Chong H., Guan K.L. Regulation of Raf through phosphorylation and N terminus-C terminus interaction. JBiol Chem 2003, 278(38):36269-36276.
23. Moodie S.A., Willumsen B.M., Weber M.J., et al. Complexes of Ras.GTP with Raf-1 and mitogen-activated protein kinase kinase. Science 1993, 260(5114):1658-1661.
24. Winkler D.G., Cutler R.E., Drugan J.K., et al. Identification of residues in the cysteine-rich domain of Raf-1 that control Ras binding and Raf-1 activity. JBiol Chem 1998, 273(34):21578-21584.
25. Garnett M.J., Rana S., Paterson H., et al. Wild-type and mutant B-RAF activate C-RAF through distinct mechanisms involving heterodimerization. Mol Cell 2005, 20(6):963-969.
26. Terai K., Matsuda M. The amino-terminal B-Raf-specific region mediates calcium-dependent homo- and hetero-dimerization of Raf. EMBO J 2006, 25(15):3556-3564.
27. Oba J., Nakahara T., Abe T., et al. Expression of c-Kit, p-ERK and cyclin D1 in malignant melanoma: an immunohistochemical study and analysis of prognostic value. JDermatol Sci 2011, 62(2):116-123.
28. Takata M., Goto Y., Ichii N., et al. Constitutive activation of the mitogen-activated protein kinase signaling pathway in acral melanomas. JInvest Dermatol 2005, 125(2):318-322.
29. Calipel A., Mouriaux F., Glotin A.L., et al. Extracellular signal-regulated kinase-dependent proliferation is mediated through the protein kinase A/B-Raf pathway in human uveal melanoma cells. JBiol Chem 2006, 281(14):9238-9250.
30. Bhatt K.V., Hu R., Spofford L.S., et al. Mutant B-RAF signaling and cyclin D1 regulate Cks1/S-phase kinase-associated protein 2-mediated degradation of p27Kip1 in human melanoma cells. Oncogene 2007, 26(7):1056-1066.
31. Bhatt K.V., Spofford L.S., Aram G., et al. Adhesion control of cyclin D1 and p27Kip1 levels is deregulated in melanoma cells through BRAF-MEK-ERK signaling. Oncogene 2005, 24(21):3459-3471.
32. Eskandarpour M., Huang F., Reeves K.A., et al. Oncogenic NRAS has multiple effects on the malignant phenotype of human melanoma cells cultured invitro. Int J Cancer 2009, 124(1):16-26.
33. Eskandarpour M., Kiaii S., Zhu C., et al. Suppression of oncogenic NRAS by RNA interference induces apoptosis of human melanoma cells. Int J Cancer 2005, 115(1):65-73.
34. Wang Y.F., Jiang C.C., Kiejda K.A., et al. Apoptosis induction in human melanoma cells by inhibition of MEK is caspase-independent and mediated by the Bcl-2 family members PUMA, Bim, and Mcl-1. Clin Cancer Res 2007, 13(16):4934-4942.
35. Verhaegen M., Bauer J.A., Martin de la Vega C., et al. Anovel BH3 mimetic reveals a mitogen-activated protein kinase-dependent mechanism of melanoma cell death controlled by p53 and reactive oxygen species. Cancer Res 2006, 66(23):11348-11359.
36. Sheridan C., Brumatti G., Martin S.J. Oncogenic B-RafV600E inhibits apoptosis and promotes ERK-dependent inactivation of Bad and Bim. JBiol Chem 2008, 283(32):22128-22135.
37. Panka D.J., Cho D.C., Atkins M.B., et al. GSK-3beta inhibition enhances sorafenib-induced apoptosis in melanoma cell lines. JBiol Chem 2008, 283(2):726-732.
38. Cartlidge R.A., Thomas G.R., Cagnol S., et al. Oncogenic BRAF(V600E) inhibits BIM expression to promote melanoma cell survival. Pigment Cell Melanoma Res 2008, 21(5):534-544.
39. Smalley K.S., Xiao M., Villanueva J., et al. CRAF inhibition induces apoptosis in melanoma cells with non-V600E BRAF mutations. Oncogene 2009, 28(1):85-94.
40. Jiang C.C., Lai F., Tay K.H., et al. Apoptosis of human melanoma cells induced by inhibition of B-RAFV600E involves preferential splicing of bimS. Cell Death Dis 2010, 1:e69.
41. Kwong L.N., Davies M.A. Navigating the therapeutic complexity of PI3K pathway inhibition in melanoma. Clin Cancer Res 2013, 19(19):5310-5319.
42. Tsao H., Zhang X., Fowlkes K., et al. Relative reciprocity of NRAS and PTEN/MMAC1 alterations in cutaneous melanoma cell lines. Cancer Res 2000, 60(7):1800-1804.
43. Tsao H., Goel V., Wu H., et al. Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanoma. JInvest Dermatol 2004, 122(2):337-341.
44. Davies M.A., Stemke-Hale K., Tellez C., et al. Anovel AKT3 mutation in melanoma tumours and cell lines. Br J Cancer 2008, 99(8):1265-1268.
45. Maertens O., Johnson B., Hollstein P., et al. Elucidating distinct roles for NF1 in melanomagenesis. Cancer Discov 2013, 3(3):338-349.
46. Zheng B., Jeong J.H., Asara J.M., et al. Oncogenic B-RAF negatively regulates the tumor suppressor LKB1 to promote melanoma cell proliferation. Mol Cell 2009, 33(2):237-247.
47. Corcoran R.B., Rothenberg S.M., Hata A.N., et al. TORC1 suppression predicts responsiveness to RAF and MEK inhibition in BRAF-mutant melanoma. Sci Transl Med 2013, 5(196):196ra98.
48. Brose M.S., Volpe P., Feldman M., et al. BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res 2002, 62(23):6997-7000.
49. Davies H., Bignell G.R., Cox C., et al. Mutations of the BRAF gene in human cancer. Nature 2002, 417(6892):949-954.
50. Heidorn S.J., Milagre C., Whittaker S., et al. Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell 2010, 140(2):209-221.
51. Poulikakos P.I., Zhang C., Bollag G., et al. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature 2010, 464(7287):427-430.
52. Long G.V., Menzies A.M., Nagrial A.M., et al. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. JClin Oncol 2011, 29(10):1239-1246.
53. Menzies A.M., Haydu L.E., Visintin L., et al. Distinguishing clinicopathologic features of patients with V600E and V600K BRAF-mutant metastatic melanoma. Clin Cancer Res 2012, 18(12):3242-3249.
54. Dummer R., Robert C., Nyakas M., et al. Initial results from a phase I, open-label, dose escalation study of the oral BRAF inhibitor LGX818 in patients with BRAF V600 mutant advanced or metastatic melanoma. JClin Oncol 2013, 31(Suppl). [abstract], Abstract 9028.
55. Kwong L.N., Costello J.C., Liu H., et al. Oncogenic NRAS signaling differentially regulates survival and proliferation in melanoma. Nat Med 2012, 18(10):1503-1510.
56. Funasaka Y., Boulton T., Cobb M., et al. c-Kit-kinase induces a cascade of protein tyrosine phosphorylation in normal human melanocytes in response to mast cell growth factor and stimulates mitogen-activated protein kinase but is down-regulated in melanomas. Mol Biol Cell 1992, 3(2):197-209.
57. Wardelmann E., Merkelbach-Bruse S., Pauls K., et al. Polyclonal evolution of multiple secondary KIT mutations in gastrointestinal stromal tumors under treatment with imatinib mesylate. Clin Cancer Res 2006, 12(6):1743-1749.
58. Curtin J.A., Busam K., Pinkel D., et al. Somatic activation of KIT in distinct subtypes of melanoma. JClin Oncol 2006, 24(26):4340-4346.
59. Carvajal R.D., Antonescu C.R., Wolchok J.D., et al. KIT as a therapeutic target in metastatic melanoma. JAMA 2011, 305(22):2327-2334.
60. Guo J., Si L., Kong Y., et al. Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification. JClin Oncol 2011, 29(21):2904-2909.
61. Hodi F.S., Corless C.L., Giobbie-Hurder A., et al. Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin. JClin Oncol 2013, 31(26):3182-3190.
62. Van Raamsdonk C.D., Bezrookove V., Green G., et al. Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi. Nature 2009, 457(7229):599-602.
63. Van Raamsdonk C.D., Griewank K.G., Crosby M.B., et al. Mutations in GNA11 in uveal melanoma. NEngl J Med 2010, 363(23):2191-2199.
64. Chen X., Wu Q., Tan L., et al. Combined PKC and MEK inhibition in uveal melanoma with GNAQ and GNA11 mutations. Oncogene 2013, 10.1038/onc.2013.418.
65. Wu X., Li J., Zhu M., et al. Protein kinase C inhibitor AEB071 targets ocular melanoma harboring GNAQ mutations via effects on the PKC/Erk1/2 and PKC/NF-kappaB pathways. Mol Cancer Ther 2012, 11(9):1905-1914.
66. von Euw E., Atefi M., Attar N., et al. Antitumor effects of the investigational selective MEK inhibitor TAK733 against cutaneous and uveal melanoma cell lines. Mol Cancer 2012, 11:22.
67. Khalili J.S., Yu X., Wang J., et al. Combination small molecule MEK and PI3K inhibition enhances uveal melanoma cell death in a mutant GNAQ- and GNA11-dependent manner. Clin Cancer Res 2012, 18(16):4345-4355.
68. Selumetinib shows promise in metastatic uveal melanoma. Cancer Discov 2013, 3(7):OF8.
69. Selumetinib increases the efficacy of first-line dacarbazine. Cancer Discov 2013, 3(7):OF16.
70. Sheppard K.E., McArthur G.A. The cell cycle regulator CDK4 an emerging therapeutic target in melanoma. Clin Cancer Res 2013, 19:5320-5328.
71. McArthur G.A., Young R.J., Sheppard K.E., et al. Clinical significance of genomic alterations of the CDK4-pathway and sensitivity to the CDK4 inhibitor PD 0332991 in melanoma. JClin Oncol 2012, 30(Suppl). [abstract], Abstract 8520.
72. Castellano M., Pollock P.M., Walters M.K., et al. CDKN2A/p16 is inactivated in most melanoma cell lines. Cancer Res 1997, 57(21):4868-4875.
73. Jonsson A., Tuominen R., Grafstrom E., et al. High frequency of p16(INK4A) promoter methylation in NRAS-mutated cutaneous melanoma. JInvest Dermatol 2010, 130(12):2809-2817.
74. Fargnoli M.C., Chimenti S., Keller G., et al. CDKN2a/p16INK4a mutations and lack of p19ARF involvement in familial melanoma kindreds. JInvest Dermatol 1998, 111(6):1202-1206.
75. Liu L., Dilworth D., Gao L., et al. Mutation of the CDKN2A 5' UTR creates an aberrant initiation codon and predisposes to melanoma. Nat Genet 1999, 21(1):128-132.
76. Liu L., Lassam N.J., Slingerland J.M., et al. Germline p16INK4A mutation and protein dysfunction in a family with inherited melanoma. Oncogene 1995, 11(2):405-412.
77. Ranade K., Hussussian C.J., Sikorski R.S., et al. Mutations associated with familial melanoma impair p16INK4 function. Nat Genet 1995, 10(1):114-116.
78. Puntervoll H.E., Yang X.R., Vetti H.H., et al. Melanoma prone families with CDK4 germline mutation: phenotypic profile and associations with MC1R variants. JMed Genet 2013, 50(4):264-270.
79. Lubbe J., Reichel M., Burg G., et al. Absence of p53 gene mutations in cutaneous melanoma. JInvest Dermatol 1994, 102(5):819-821.
80. Muthusamy V., Hobbs C., Nogueira C., et al. Amplification of CDK4 and MDM2 in malignant melanoma. Genes Chromosomes Cancer 2006, 45(5):447-454.
81. Polsky D., Bastian B.C., Hazan C., et al. HDM2 protein overexpression, but not gene amplification, is related to tumorigenesis of cutaneous melanoma. Cancer Res 2001, 61(20):7642-7646.
82. Tsao H., Zhang X., Benoit E., et al. Identification of PTEN/MMAC1 alterations in uncultured melanomas and melanoma cell lines. Oncogene 1998, 16(26):3397-3402.
83. Nathanson K.L., Martin A.M., Wubbenhorst B., et al. Tumor genetic analyses of patients with metastatic melanoma treated with the BRAF inhibitor dabrafenib (GSK2118436). Clin Cancer Res 2013, 19(17):4868-4878.
84. Shi H., Hugo W., Kong X., et al. Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy. Cancer Discov 2014, 4(1):80-93.
85. Wee S., Wiederschain D., Maira S.M., et al. PTEN-deficient cancers depend on PIK3CB. Proc Natl Acad Sci USA 2008, 105(35):13057-13062.
86. Su Y., Vilgelm A.E., Kelley M.C., et al. RAF265 inhibits the growth of advanced human melanoma tumors. Clin Cancer Res 2012, 18(8):2184-2198.
87. Wilhelm S.M., Adnane L., Newell P., et al. Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther 2008, 7(10):3129-3140.
88. Beeram M., Patnaik A., Rowinsky E.K. Raf: a strategic target for therapeutic development against cancer. JClin Oncol 2005, 23(27):6771-6790.
89. Smalley K.S., Flaherty K.T. Development of a novel chemical class of BRAF inhibitors offers new hope for melanoma treatment. Future Oncol 2009, 5(6):775-778.
90. Wilhelm S., Carter C., Lynch M., et al. Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Discov 2006, 5(10):835-844.
91. Chen J., Shen Q., Labow M., et al. Protein kinase D3 sensitizes RAF inhibitor RAF265 in melanoma cells by preventing reactivation of MAPK signaling. Cancer Res 2011, 71(12):4280-4291.
92. Amaravadi R.K., Schuchter L.M., McDermott D.F., et al. Phase II trial of temozolomide and sorafenib in advanced melanoma patients with or without brain metastases. Clin Cancer Res 2009, 15(24):7711-7718.
93. Eisen T., Ahmad T., Flaherty K.T., et al. Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis. Br J Cancer 2006, 95(5):581-586.
94. Flaherty K.T., Lee S.J., Zhao F., et al. Phase III trial of carboplatin and paclitaxel with or without sorafenib in metastatic melanoma. JClin Oncol 2013, 31(3):373-379.
95. Flaherty K.T., Schiller J., Schuchter L.M., et al. Aphase I trial of the oral, multikinase inhibitor sorafenib in combination with carboplatin and paclitaxel. Clin Cancer Res 2008, 14(15):4836-4842.
96. Hauschild A., Agarwala S.S., Trefzer U., et al. Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. JClin Oncol 2009, 27(17):2823-2830.
97. Margolin K.A., Moon J., Flaherty L.E., et al. Randomized phase II trial of sorafenib with temsirolimus or tipifarnib in untreated metastatic melanoma (S0438). Clin Cancer Res 2012, 18(4):1129-1137.
98. McDermott D.F., Sosman J.A., Gonzalez R., et al. Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group. JClin Oncol 2008, 26(13):2178-2185.
99. Sharfman W.H., Hodi F.S., Lawrence D.P., et al. Results from the first-in-human (FIH) phase I study of the oral RAF inhibitor RAF265 administered daily to patients with advanced cutaneous melanoma. JClin Oncol 2011, 29(Suppl). [abstract], Abstract 8508.
100. Joseph E.W., Pratilas C.A., Poulikakos P.I., et al. The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner. Proc Natl Acad Sci USA 2010, 107(33):14903-14908.
101. Flaherty K.T., Puzanov I., Kim K.B., et al. Inhibition of mutated, activated BRAF in metastatic melanoma. NEngl J Med 2010, 363(9):809-819.
102. Sosman J.A., Kim K.B., Schuchter L., et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. NEngl J Med 2012, 366(8):707-714.
103. Ugurel S., Hildenbrand R., Zimpfer A., et al. Lack of clinical efficacy of imatinib in metastatic melanoma. Br J Cancer 2005, 92(8):1398-1405.
104. Wyman K., Atkins M.B., Prieto V., et al. Multicenter phase II trial of high-dose imatinib mesylate in metastatic melanoma: significant toxicity with no clinical efficacy. Cancer 2006, 106(9):2005-2011.
105. Morton D., Eilber F.R., Malmgren R.A., et al. Immunological factors which influence response to immunotherapy in malignant melanoma. Surgery 1970, 68(1):158-163. [discussion: 63-4].
106. Morton D.L., Eilber F.R., Holmes E.C., et al. BCG immunotherapy of malignant melanoma: summary of a seven-year experience. Ann Surg 1974, 180(4):635-643.
107. Atkins M.B., Lotze M.T., Dutcher J.P., et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. JClin Oncol 1999, 17(7):2105-2116.
108. Kirkwood J.M., Strawderman M.H., Ernstoff M.S., et al. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. JClin Oncol 1996, 14(1):7-17.
109. Atkins M.B., Kunkel L., Sznol M., et al. High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update. Cancer J Sci Am 2000, 6(Suppl 1):S11-S14.
110. Hamid O., Robert C., Daud A., et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. NEngl J Med 2013, 369(2):134-144.
111. Topalian S.L., Hodi F.S., Brahmer J.R., et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. NEngl J Med 2012, 366(26):2443-2454.
112. Sullivan R.J., Lorusso P.M., Flaherty K.T. The intersection of immune-directed and molecularly targeted therapy in advanced melanoma: where we have been, are, and will be. Clin Cancer Res 2013, 19(19):5283-5291.
113. Frederick D.T., Piris A., Cogdill A.P., et al. BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma. Clin Cancer Res 2013, 19(5):1225-1231.
114. Hong D.S., Vence L., Falchook G., et al. BRAF(V600) inhibitor GSK2118436 targeted inhibition of mutant BRAF in cancer patients does not impair overall immune competency. Clin Cancer Res 2012, 18(8):2326-2335.
115. Wilmott J.S., Long G.V., Howle J.R., et al. Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma. Clin Cancer Res 2012, 18(5):1386-1394.
116. Boni A., Cogdill A.P., Dang P., et al. Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function. Cancer Res 2010, 70(13):5213-5219.
117. Comin-Anduix B., Chodon T., Sazegar H., et al. The oncogenic BRAF kinase inhibitor PLX4032/RG7204 does not affect the viability or function of human lymphocytes across a wide range of concentrations. Clin Cancer Res 2010, 16(24):6040-6048.
118. Ribas A., Hodi F.S., Callahan M., et al. Hepatotoxicity with combination of vemurafenib and ipilimumab. NEngl J Med 2013, 368(14):1365-1366.
119. Joseph R.W., Sullivan R.J., Harrell R., et al. Correlation of NRAS mutations with clinical response to high-dose IL-2 in patients with advanced melanoma. JImmunother 2012, 35(1):66-72.
120. Shahabi V., Whitney G., Hamid O., et al. Assessment of association between BRAF-V600E mutation status in melanomas and clinical response to ipilimumab. Cancer Immunol Immunother 2012, 61(5):733-737.
121. Johnson D.B., Lovly C.M., Flavin M., et al. NRAS mutation: a potential biomarker of clinical response to immune-based therapies in metastatic melanoma (MM). JClin Oncol 2013, 31(Suppl). [abstract], Abstract 9019.